(HealthDay News) — The drug Tagrisso could offer hope to patients battling a form of lung cancer that typically hits people with little or no history of smoking, a new trial finds. Taken after surgery to remove the lung tumor, Tagrisso (osimertinib) greatly extended the average survival of people battling a non-metastatic form of non-small cell lung cancer (NSCLC), which makes up the vast majority of lung cancers. The NSCLC tumors that were the focus of the new trial were characterized by the presence of an epidermal growth factor receptor (EGFR) mutation on cells. This subset of tumors “are present in roughly 10% of Caucasian patients, with much higher estimates of other patient populations, such as Asian patients,” said Dr. Kevin Sullivan, a lung cancer specialist who wasn’t involved in the new trial. “Most patients with these mutations are non-smokers or former very light smokers,” noted Sullivan, who works in the division of medical oncology at Northwell Health Cancer Institute in Lake Success, N.Y. Typically, he said, patients diagnosed with these tumors get surgery followed by standard chemotherapy — if the cancer hasn’t already spread beyond the lung. That standard follow-up chemotherapy “provides a small but significant survival benefit — meaning, it improves the cure rate,” Sullivan explained. And if the cancer comes back, which it often does, it can prove incurable. The new study,… read on >







